JP2022542434A5 - - Google Patents

Info

Publication number
JP2022542434A5
JP2022542434A5 JP2022506384A JP2022506384A JP2022542434A5 JP 2022542434 A5 JP2022542434 A5 JP 2022542434A5 JP 2022506384 A JP2022506384 A JP 2022506384A JP 2022506384 A JP2022506384 A JP 2022506384A JP 2022542434 A5 JP2022542434 A5 JP 2022542434A5
Authority
JP
Japan
Prior art keywords
disease
cancers
syndrome
vitiligo
autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2022506384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542434A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/044558 external-priority patent/WO2021022186A1/en
Publication of JP2022542434A publication Critical patent/JP2022542434A/ja
Publication of JP2022542434A5 publication Critical patent/JP2022542434A5/ja
Ceased legal-status Critical Current

Links

JP2022506384A 2019-07-31 2020-07-31 重水素化mk2経路阻害剤およびその使用方法 Ceased JP2022542434A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962881026P 2019-07-31 2019-07-31
US62/881,026 2019-07-31
PCT/US2020/044558 WO2021022186A1 (en) 2019-07-31 2020-07-31 Deuterated mk2 pathway inhibitors and methods of using the same

Publications (2)

Publication Number Publication Date
JP2022542434A JP2022542434A (ja) 2022-10-03
JP2022542434A5 true JP2022542434A5 (cg-RX-API-DMAC7.html) 2023-07-19

Family

ID=74228512

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506384A Ceased JP2022542434A (ja) 2019-07-31 2020-07-31 重水素化mk2経路阻害剤およびその使用方法

Country Status (12)

Country Link
US (1) US12403141B2 (cg-RX-API-DMAC7.html)
EP (1) EP4003344A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022542434A (cg-RX-API-DMAC7.html)
KR (1) KR20220041180A (cg-RX-API-DMAC7.html)
CN (1) CN114206339A (cg-RX-API-DMAC7.html)
AU (1) AU2020319879A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022001324A2 (cg-RX-API-DMAC7.html)
CA (1) CA3149304A1 (cg-RX-API-DMAC7.html)
IL (1) IL290045A (cg-RX-API-DMAC7.html)
MX (1) MX2022001151A (cg-RX-API-DMAC7.html)
PH (1) PH12022550029A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021022186A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296054A (en) 2020-03-27 2022-10-01 Aclaris Therapeutics Inc Oral compositions of mk2 pathway inhibitor for treatment of immune conditions
WO2022212489A1 (en) 2021-03-31 2022-10-06 Xinthera, Inc. Mk2 inhibitors and uses thereof
US11685719B2 (en) 2021-07-09 2023-06-27 Xinthera, Inc. Pyridinone MK2 inhibitors and uses thereof
WO2023001282A1 (zh) * 2021-07-23 2023-01-26 南京明德新药研发有限公司 杂环取代的嘧啶衍生物
CN116444492B (zh) * 2021-12-29 2026-03-03 上海美悦生物科技发展有限公司 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途
CN116396274B (zh) * 2022-01-06 2025-11-11 深圳信立泰药业股份有限公司 一种取代的联吡啶酮类化合物及其制备方法与应用
CN116444493A (zh) * 2022-01-14 2023-07-18 上海翰森生物医药科技有限公司 含双并环类衍生物、其制备方法和应用
EP4464694A4 (en) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE
US20230286950A1 (en) * 2022-02-04 2023-09-14 Aclaris Therapeutics, Inc. Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds
CN119384410B (zh) * 2022-03-03 2026-06-12 深圳信立泰药业股份有限公司 一种氘代三联吡啶二酮化合物或其盐及其制备方法与应用
US20260217652A1 (en) * 2023-01-13 2026-07-30 Shanghai Meiyue Biotech Development Co., Ltd. Phenyl-substituted heteroaryl compound and pharmaceutical composition comprising same, preparation method therefor and use thereof
JP2026504073A (ja) * 2023-01-13 2026-02-03 プールベグ ファーマ(ユーケー) リミテッド がん免疫療法関連サイトカイン放出症候群の軽減のための医薬品および方法
WO2025093869A1 (en) * 2023-11-01 2025-05-08 Poolbeg Pharma (UK) Limited P38 map kinase inhibitor for use in the treatment of inflammation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080280886A1 (en) * 2007-05-08 2008-11-13 Auspex Pharmaceuticals, Inc. Substituted ureas
CA2763565A1 (en) * 2009-05-28 2010-12-02 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
US8575348B2 (en) * 2009-07-28 2013-11-05 Auspex Pharmaceuticals, Inc Quinolone inhibitors of lipoprotein-associated phospholipase A2
DK2648516T3 (da) * 2010-12-06 2019-01-02 Aclaris Therapeutics Inc Substituerede pyridinon-pyridinylforbindelser
US9359300B2 (en) * 2010-12-06 2016-06-07 Confluence Life Sciences, Inc. Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
KR102313515B1 (ko) 2013-06-07 2021-10-14 어클라리스 쎄라퓨틱스, 인코포레이티드 메틸/플루오로-피리디닐-메톡시 치환된 피리디논-피리디닐 화합물 및 플루오로-피리미디닐-메톡시 치환된 피리디논-피리디닐 화합물
CZ2015601A3 (cs) * 2015-09-02 2017-03-15 Zentiva, K.S. Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jejích deuterovaných analog neobsahujících dimerické nečistoty
AU2017250086A1 (en) * 2016-04-11 2018-09-20 Clexio Biosciences Ltd. Deuterated ketamine derivatives
WO2018229683A1 (en) * 2017-06-15 2018-12-20 Novartis Ag 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
CN111727042A (zh) * 2017-12-06 2020-09-29 仁新医药私人有限公司 微管蛋白抑制剂
WO2021178449A1 (en) 2020-03-02 2021-09-10 Washington University Compositions and methods for the treatment of pancreatic cancer

Similar Documents

Publication Publication Date Title
JP2022531088A5 (cg-RX-API-DMAC7.html)
JP2021534244A5 (cg-RX-API-DMAC7.html)
ES2985542T3 (es) Compuesto inhibidor de JAK y uso del mismo
JP7580136B2 (ja) Jak阻害剤化合物及びその使用
JP2021502400A5 (cg-RX-API-DMAC7.html)
JP2020512315A5 (cg-RX-API-DMAC7.html)
JP2020511468A5 (cg-RX-API-DMAC7.html)
ES2277858T3 (es) Heterociclos de nitrogeno biciclicos alquilamino sustituidos como inhibidores de proteina kinasa p38.
DE60209381T2 (de) N-substituierte hydroxypyrimidinoncarboxamid-hemmer der hiv-integrase
JP2022137194A (ja) 神経刺激性ステロイド、組成物、およびその使用
JP2020128420A (ja) Cns障害を処置するための組成物および方法
DE69920732T2 (de) Bicyclische stickstoffheteroaryl verbindungen
TWI842766B (zh) 三環janus 激酶1 抑制劑及其組合物和方法
ES2430210T3 (es) Derivados de 4-aminopirimidina como antagonistas del receptor de histamina H4
JP2017529367A5 (cg-RX-API-DMAC7.html)
EA027879B1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
CN111689959A (zh) 作为fgfr4抑制剂的杂环化合物
CN113166193A (zh) 用于治疗cns病症的在位置10处被环状基团取代的神经活性类固醇
CN113993585B (zh) 双环jak抑制剂及其用途
JP2022551316A5 (cg-RX-API-DMAC7.html)
TW202227448A (zh) 製備jak抑制劑之方法及中間體
JP7164619B2 (ja) 新規ブラジキニンb2受容体アンタゴニスト
CN120904157A (zh) 杂芳基化合物及其制备方法和用途
CN118702683A (zh) 吡唑基-氨基-嘧啶基衍生物的苯醚和苯胺及其组合物和方法
AU2019206560B2 (en) Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators